Affimed (AFMD) Reports Q4 Loss of EUR0.60/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Affimed (AFMD) Reports FY22, Provides Operational Update
March 23, 2023 6:31 AM EDTAffimed N.V. (Nasdaq: AFMD) today reported financial results for the year ended December 31, 2022, and provided an update on clinical and corporate progress.
During 2022, we presented data across our pipeline that show our innate cell engagers can deliver unprecedented efficacy when combined with NK cells, can activate and direct cytotoxic T cells to tumor cells, and deliver meaningful single agent activity with a differentiated safety profile, said Adi Hoess, Chief Executive Officer at Affimed. Supported by a cash runway into 2025, our Company is well positioned to execute on our strategic imperatives, with... More
